DelveInsight’s “Next Generation Immunotherapies Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Next Generation Immunotherapies, historical and forecasted epidemiology, as well as the Next Generation Immunotherapies market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Next Generation Immunotherapies Market with DelveInsight’s In-Depth Report @ Next Generation Immunotherapies Market Size
Key Takeaways from the Next Generation Immunotherapies Market Report
The leading Next Generation Immunotherapies companies include Bristol-Myers Squibb, Regeneron, Novartis, GlaxoSmithKline, Merck, Roche, AstraZeneca, and others.
Rising prevalence of cancer and autoimmune diseases globally is accelerating demand for advanced immunotherapies offering durable and targeted treatment outcomes.
Breakthroughs in CAR-T, TCR therapies, bispecific antibodies, and immune checkpoint modulators are expanding therapeutic applications and improving clinical efficacy.
The Next Generation Immunotherapies market in the 7MM is expected to witness major change during the study period 2020–2034.
Key targets currently under development include LAG-3, TIGIT, NKG2A, CD73, TIM-3, B7-H3, A2A receptor, FAK, CD47-SIRPα receptor, and CSF-1, among others.
Stay ahead in the Next Generation Immunotherapies Market with DelveInsight’s Strategic Report @ Next Generation Immunotherapies Market Outlook
Next Generation Immunotherapies Epidemiology Segmentation in the 7MM
Total Next Generation Immunotherapies Market Size
Market Size by Therapies
Market Size by Class
Next Generation Immunotherapies Treatment Market
Next Generation Immunotherapies Pipeline Analysis
OPDUALAG (relatlimab/nivolumab): Bristol-Myers Squibb OPDUALAG is a first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion. It is the first LAG-3 inhibitor granted FDA approval in March 2022 for the treatment of adult and pediatric patients aged 12 years or older with unresectable or metastatic melanoma.
Fianlimab (REGN-3767): Regeneron Pharmaceuticals Fianlimab is a fully human monoclonal antibody targeting the immune checkpoint receptor LAG-3 on T cells. In melanoma, LAG-3 expression on cancer cells is associated with therapeutic resistance to PD-1 inhibitors. It is being investigated in combination with Regeneron’s PD-1 inhibitor Libtayo to determine whether concurrent blockade of LAG-3 and PD-1 can help overcome resistance and enhance T-cell activation.
Cobolimab (GSK-4069889): GlaxoSmithKline Cobolimab is a monoclonal antibody targeting the inhibitory T-cell receptor TIM-3 (T-cell immunoglobulin and mucin domain-containing protein 3), with potential immune checkpoint inhibitory and antineoplastic activities.
Tiragolumab (RG-6058): Roche Tiragolumab is a novel immune checkpoint inhibitor with an intact Fc region that selectively binds to TIGIT, a novel inhibitory immune checkpoint that suppresses the immune response to cancer.
Ezabenlimab (BI-754091): Boehringer Ingelheim Ezabenlimab is a monoclonal antibody antagonist of the key myeloid cell checkpoint inhibitor SIRPα, preventing the SIRPα ligand CD47 from binding to SIRPα and thereby preserving the anti-tumorigenic properties of myeloid cells such as macrophages and dendritic cells.
Next Generation Immunotherapies Market Insights
The current treatment landscape includes checkpoint inhibitors, monoclonal antibody inhibitors, immune system modulators, vaccines, virus therapies, adoptive cell transfer, T-cell therapy, and targeted therapies.
Cancer immunotherapy is now considered the “fifth pillar” of cancer therapy, joining surgery, cytotoxic chemotherapy, radiation, and targeted therapy.
The competitive landscape is highly dynamic and innovation-driven, with leading players advancing CAR-T and CAR-NK cell therapies, bispecific and multispecific antibodies, immune checkpoint inhibitors, and cancer vaccines.
Strategic collaborations, licensing agreements, and mergers are common as companies seek to strengthen pipelines and access novel platforms.
The expected introduction of emerging therapies with improved efficacy, greater awareness initiatives, and further improvement in diagnosis rates are likely to boost market growth across the 7MM.
Get In-Depth Knowledge on Next Generation Immunotherapies Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/next-generation-immunotherapies-market
Next Generation Immunotherapies Market Outlook
Cancer immunotherapy harnesses the patient’s own immune system to fight cancer, distinguishing it from conventional therapies that directly target tumor cells. Immune checkpoints are pathways with inhibitory or stimulatory features that maintain self-tolerance and assist with immune response. Well-described checkpoints include CTLA-4, PD-1, and PD-L1. The Next Generation Immunotherapies pipeline is very robust, with many potential therapies under investigation, and the treatment space is expected to experience a significant market impact during the forecast period. Market growth may be offset by therapy failures or discontinuations, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.
Scope of the Next Generation Immunotherapies Market Report
Coverage: 7MM
Study Period: 2020–2034
Forecast Period: 2024–2034
Next Generation Immunotherapies Companies: Bristol-Myers Squibb, Regeneron, GlaxoSmithKline, Roche, Boehringer Ingelheim, and others
Next Generation Immunotherapies Therapies: OPDUALAG, Fianlimab, Cobolimab, Tiragolumab, Ezabenlimab, and others
Next Generation Immunotherapies Market Access & Reimbursements, Unmet Needs and Perspectives
Next Generation Immunotherapies SWOT Analysis and KOL Views
Unlock Strategic Insights with DelveInsight’s Comprehensive Next Generation Immunotherapies Market Report @ Next Generation Immunotherapies Market Drivers and Barriers
Table of Contents
1. Key Insights
2. Report Introduction
3. NGIs Market Overview at a Glance
3.1. Market Share (%) Distribution of NGIs in 2020: By Country
3.2. Market Share (%) Distribution of NGIs in 2034: By Country
3.3. Market Share (%) Distribution of NGIs in 2025: By Indication
3.4. Market Share (%) Distribution of NGIs in 2034: By Indication
4. Key Highlights from Report
5. Executive Summary of NGIs
5.1. Key Events
6. Epidemiology and Market Forecast Flow
7. Background and Overview
7.1. Introduction
7.2. Different types of NGIs
7.3. Applications of NGIs
7.4. Mechanisms of Action of NGIs for Cancer Therapy
7.5. Routes of Administration
7.5.1. Direct intratumoral delivery
7.5.2. IV delivery
7.5.3. Other routes of delivery
7.5.4. Comparing different administration routes
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Epidemiology Scenario in the 7MM
8.3.1. Total Incident cases of target indications across the 7MM
8.3.2. Target Patient Pool of NGIs across the 7MM
8.3.3. Treated cases by line of therapy across the 7MM
8.4. Epidemiology Scenario in the US
8.4.1. Total Incident cases of target indications across the US
8.4.2. Target Patient Pool of NGIs across the US
8.4.3. Treated cases by line of therapy across the US
8.5. Epidemiology Scenario in EU5
8.5.1. Total Incident cases of target indications across EU5
8.5.2. Target Patient Pool of NGIs across EU5
8.5.3. Treated cases by line of therapy across EU5
8.6. Epidemiology Scenario in Japan
8.6.1. Total Incident cases of target indications across Japan
8.6.2. Indication wise target patient pool across Japan
8.6.3. Treated cases by line of therapy across Japan
9. Key Endpoints in NGIs
10. Marketed therapies
10.1. Key Cross of Marketed Therapies
10.2. OPDUALAG: Bristol Myers Squibb
10.2.1. Product description
10.2.2. Regulatory milestones
10.2.3. Other developmental activities
10.2.4. Pivotal clinical trial
10.2.5. Ongoing pipeline activity
11. Emerging Therapies
11.1. Key Cross Competition
11.2. Fianlimab (REGN-3767) : Regeneron Pharmaceuticals
11.2.1. Product description
11.2.2. Other developmental activities
11.2.3. Clinical development
11.2.4. Safety and efficacy
11.3. Tebotelimab (MGD013) : MacroGenics
11.3.1. Product description
11.3.2. Other developmental activities
11.3.3. Clinical development
11.3.4. Safety and efficacy
11.4. Ezabenlimab (BI-754091): Boehringer Ingelheim
11.4.1. Product description
11.4.2. Other developmental activities
11.4.3. Clinical development
11.4.4. Safety and efficacy
11.5. MGC 018 : MacroGenics
11.5.1. Product description
11.5.2. Other Developmental Activities
11.5.3. Clinical development
11.5.4. Safety and efficacy
11.6. Etigilimab : MereoBiopharma
11.6.1. Product description
11.6.2. Other developmental activities
11.6.3. Clinical development
11.6.4. Safety and efficacy
11.7. HB-0036 : Hubao Biopharm
11.7.1. Product description
11.7.2. Other developmental activities
11.7.3. Clinical development
11.7.4. Safety and efficacy
To be continued in the report…
12. Attribute Analysis
13. Next Generation Immunotherapies: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Market Size of NGIs in the 7MM
13.3.1. Total Market Size of NGIs
13.3.2. Total Market Size of NGIs by Indications in the 7MM
13.3.3. Market Size of NGIs by Therapies
13.4. Market Size of NGIs in the US
13.4.1. Total Market Size of NGIs
13.4.2. Total Market Size of NGIs by Indications
13.4.3. Market Size of NGIs by Therapies in the US
13.5. Market Size of NGIs in EU5
13.5.1. Total Market Size of NGIs
13.5.2. Total Market Size of NGIs by Indications
13.5.3. Market Size of NGIs by Therapies in EU5
13.6. Market Size of NGIs in Japan
13.6.1. Total Market Size of NGIs
13.6.2. Total Market Size of NGIs by Indications
13.6.3. Market Size of NGIs by Therapies in Japan
14. Market Access and Reimbursement
14.1. NICE UK
14.2. IQWiG and GBA Assessment
14.3. Japan
14.4. Patient assistance programs
15. KOL Views
16. SWOT Analysis
17. Unmet Needs
18. Appendix
18.1. Acronyms and Abbreviations
18.2. Bibliography
18.3. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports
LAG-3 Next-generation Immunotherapy- Competitive Landscape and Market Forecast–2035
DelveInsight’s “Lymphocyte Activation Gene-3 (LAG-3) Competitive Landscape and Market Forecast – 2035” report delivers an in-depth understanding of the LAG-3, historical and forecasted market trends of LAG-3 in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Key LAG-3 Next-generation Immunotherapy companies working in the LAG-3 Next-generation Immunotherapy market are Bristol-Myers Squibb, Merck Sharp & Dohme Corp., MacroGenics, Immutep, Incyte Corporation, F-star Therapeutics, EpimAb Biotherapeutics, Roche, Xencor, AnaptysBio, GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi, Symphogen, and others.
ICOS-Next Generation Immunotherapy – Competitive Landscape and Market Forecast – 2035
DelveInsight’s ‘ICOS-Next Generation Immunotherapy Competitive Landscape and Market Forecast–2035’ report delivers an in-depth understanding of the ICOS as well as the ICOS-Next Generation Immunotherapy therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/next-generation-immunotherapies-market
